Dual inhibition of MEK and mTOR dramatically blocked FBXL6- and KRAS activation-driven HCC, and this information may provide a potential targeted approach for treating this cohort of HCC patients. The gene discussed is KRAS; the disease is hepatocellular carcinoma.